Relay Therapeutics, Inc. 4

Chief Corporate Development Officer Peter Rahmer sold 4,508 shares of Relay Therapeutics, Inc. (RLAY) common stock for about $90,000 under a Rule 10b5-1 plan.

On August 26, 2026, Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc., sold 4,508 shares of the company’s common stock at a weighted average price of approximately $20.03 per share, for total proceeds of about $90,260, under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2025. The sale was executed in multiple trades within a price range of $20.00 to $20.11, and following the transaction Rahmer directly owned 223,657 shares of common stock, which includes 6,102 shares underlying restricted stock units. Based on the transaction price, his post-transaction holdings have an estimated market value of roughly $4.48 million.

Filing Facts

CIK

1812364

Ticker

RLAY

Form

4

Source Type

fda

Accession

0001193125-26-374645

Alert Tier

5